Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05367388




Registration number
NCT05367388
Ethics application status
Date submitted
3/05/2022
Date registered
10/05/2022
Date last updated
15/06/2022

Titles & IDs
Public title
A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants
Scientific title
An Open-Label, Multi-Center, Randomized, 2-Way Crossover Study to Assess the Bioequivalence of APL-101 Capsule vs PLB-1001 Capsule in Healthy Chinese and Caucasian Subjects
Secondary ID [1] 0 0
APL-101-03
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bioequivalence 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - APL-101
Treatment: Drugs - PLB-1001

Experimental: Treatment Sequence A/P - Subject will receive a single oral dose (200mg) of Treatment A on Day 1, followed by a 7-day washout period. On Day 8, the subject will begin the second treatment period by receiving a single oral dose (200 mg) of Treatment P.

Experimental: Treatment Sequence P/A - Subject will receive a single oral dose (200mg) of Treatment P on Day 1, followed by a 7-day washout period. On Day 8, the subject will begin the second treatment period by receiving a single oral dose (200 mg) of Treatment A.


Treatment: Drugs: APL-101
APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.
The treatments to be administered in this study include:
• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc.

Treatment: Drugs: PLB-1001
PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.
The treatments to be administered in this study include:
• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Area under the plasma concentration versus time curve (AUC)
Timepoint [1] 0 0
Day 1 to Day 14
Primary outcome [2] 0 0
Maximum observed plasma concentration
Timepoint [2] 0 0
Day 1 to Day 14
Secondary outcome [1] 0 0
Time to the maximum observed plasma concentration
Timepoint [1] 0 0
Day 1 to Day 14
Secondary outcome [2] 0 0
Number of adverse events observed
Timepoint [2] 0 0
Day 1 to Day 20-22
Secondary outcome [3] 0 0
Apparent plasma terminal elimination half-life
Timepoint [3] 0 0
Day 1 to Day 14

Eligibility
Key inclusion criteria
Major

- Must be Chinese (1st generation or 2nd generation Chinese with both Chinese parents),
or Caucasian.

- Body mass index between 18.0 and 30.0 kg/m2, inclusive.

- In good health, determined by no clinically significant findings from medical history,
physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory
evaluations at screening and at check-in as assessed by the Investigator (or
designee). Screening clinical laboratory evaluations may be repeated once at the
discretion of the Investigator.

- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 1.5 × the upper
limit of normal (ULN), total bilirubin = 1.5 × ULN at screening and check-in. Subjects
with ALT or AST >1.0 × ULN combined with total bilirubin >1.0 × ULN are excluded.

- QT interval corrected for heart rate using Fridericia's method (QTcF) = 450 msec
confirmed by calculating the mean of the triplicate measurements within 4 weeks prior
to Day 1.

- Systolic blood pressure between 100 and 140 mmHg or diastolic blood pressure between
50 and 90 mmHg, confirmed by calculating the mean of the triplicate measurements
within 4 weeks prior to Day 1.

Major
Minimum age
18 Years
Maximum age
55 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Significant history or clinical manifestation of any metabolic, allergic,
dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as
determined by the Investigator.

- History of significant hypersensitivity, intolerance, or allergy to any drug compound,
food, or other substance, unless approved by the Investigator.

- Have positive Coronavirus Disease 2019 (COVID-19) test at screening and/or at
check-in, have clinical signs or symptoms of COVID-19 as determined by the
Investigator, or have ongoing significant complication(s) from prior COVID-19
infection.

- Use or intend to use any nonprescription medications/products including vitamins,
minerals, and phytotherapeutic/herbal/plant derived preparations within 14 days prior
to check in, unless deemed acceptable by the Investigator.

- Have previously completed or withdrawn from this study or any other study
investigating APL 101 or similar drug product, and/or have previously received APL 101
or similar drug product.

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Unknown status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/05/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2022
Actual
Sample size
Target
48
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Auckland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Apollomics Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 1, open-label, multi-center, randomized, 2-period, adaptive design, crossover
study to assess the bioequivalence of APL-101 (Vebreltinib) capsules and PLB-1001 (Bozitinib)
capsules.

The treatments to be administered orally in this study include:

- Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose),
manufactured for Apollomics, Inc

- Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured
for Beijing Pearl Biotechnology Co., Ltd.

APL-101 capsules (Treatment A) and PLB-1001 capsules (Treatment P) are similar drug products.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05367388
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Marietta Franco, MS
Address 0 0
Apollomics Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Yufei Chen, MS
Address 0 0
Country 0 0
Phone 0 0
650-209-4055
Fax 0 0
Email 0 0
Yufei.Chen@apollomicsinc.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05367388